According to the latest guidelines on lipid-lowering treatment of the European Society of Cardiology (8), patients with FH who have not achieved target LDL-C levels should be treated with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.